| Title |
Cost Effectiveness of Targeted High-dose Atorvastatin Therapy Following Genotype Testing in Patients with Acute Coronary Syndrome
|
|---|---|
| Published in |
PharmacoEconomics, April 2013
|
| DOI | 10.1007/s40273-013-0054-5 |
| Pubmed ID | |
| Authors |
Anju Parthan, Kevin J. Leahy, Amy K. O’Sullivan, Olga A. Iakoubova, Lance A. Bare, James J. Devlin, Milton C. Weinstein |
| Abstract |
Results from the PROVE IT trial suggest that patients with acute coronary syndrome (ACS) treated with atorvastatin 80 mg/day (A80) have significantly lower rates of cardiovascular events compared with patients treated with pravastatin 40 mg/day (P40). In a genetic post hoc substudy of the PROVE IT trial, the rate of event reduction was greater in carriers of the Trp719Arg variant in kinesin family member 6 protein (KIF6) than in noncarriers. We assessed the cost effectiveness of testing for the KIF6 variant followed by targeted statin therapy (KIF6 Testing) versus not testing patients (No Test) and treating them with P40 or A80 in the USA from a payer perspective. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 2% |
| Unknown | 42 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 23% |
| Student > Master | 6 | 14% |
| Student > Postgraduate | 5 | 12% |
| Other | 4 | 9% |
| Student > Ph. D. Student | 3 | 7% |
| Other | 5 | 12% |
| Unknown | 10 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 28% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 12% |
| Economics, Econometrics and Finance | 3 | 7% |
| Social Sciences | 3 | 7% |
| Agricultural and Biological Sciences | 2 | 5% |
| Other | 5 | 12% |
| Unknown | 13 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 April 2013.
All research outputs
#15,270,134
of 22,707,247 outputs
Outputs from PharmacoEconomics
#1,483
of 1,813 outputs
Outputs of similar age
#124,032
of 198,479 outputs
Outputs of similar age from PharmacoEconomics
#25
of 30 outputs
Altmetric has tracked 22,707,247 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,813 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 198,479 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.